MedicalResearch.com Interview with:
Annette Bruchfeld MD, PhD Senior Consultant
Dept of Renal Medicine, M99
Karolinska University Hospital Huddinge
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: In patients with stage 4–5 chronic kidney disease(CKD), hepatitis C virus (HCV) infection can accelerate the decline in kidney function, impair health-related quality of life (HRQOL), and decrease survival chances of both patients and grafts in transplantation recipients.
In this study additional data from patients with stage 4–5 chronic kidney disease undergoing treatment for HCV infection in the C-SURFER study, including HRQOL and resistance analyses was presented not previously reported for this patient population with gwnotype 1 infection.
The final virological analysis of this study indicated a high cure rate with sustained virological response at 12 weeks after the end of treatment (SVR12) in more than 98% of all treated patients. Even in patients with resistance-associated substitutions (RASs) the SVR was high in 11 (84·6%) of 13 patients genotype 1a infection.
MedicalResearch.com: What should readers take away from your report?
Response: The complete data set from our study confirm the efficacy of this combination regimen (elbasvir plus grazoprevir) in patients with stage 4–5 chronic kidney disease and supports its use in the treatment of HCV in this underserved patient group.
MedicalResearch.com: What recommendations do you have for future research as a result of this study?
Response: Treatment of HCV-infected CKD patients lags far behind that of the general population. Nephrologist need to be involved in treatment decisions in CKD patients.
Disclosures: Annette Bruchfeld served on advisory committees for Merck.
MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.
Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4–5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial
Bruchfeld, Annette et al.
The Lancet Gastroenterology & Hepatology , Volume 0 , Issue 0
Published 30 May 2017
Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.
More Medical Research Interviews on MedicalResearch.com